Trial Profile
Double Blind, Two Dose, Cross-over Clinical Trial of the Positive Allosteric Modulator at the alpha7 Nicotinic Cholinergic Receptor AVL-3288 in Schizophrenia Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2019
Price :
$35
*
At a glance
- Drugs AVL 3288 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 17 Jan 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 11 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.